Cart
sales@molnova.com
DPH
CAS No. 484049-04-9
DPH( —— )
Catalog No. M14620 CAS No. 484049-04-9
A cell-permeable, small-molecule c-Abl kinase activator with pEC50 of 6.1(EC50=794 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 73 | In Stock |
|
| 5MG | 65 | In Stock |
|
| 10MG | 107 | In Stock |
|
| 25MG | 235 | In Stock |
|
| 50MG | 368 | In Stock |
|
| 100MG | 550 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDPH
-
NoteResearch use only, not for human use.
-
Brief DescriptionA cell-permeable, small-molecule c-Abl kinase activator with pEC50 of 6.1(EC50=794 nM).
-
DescriptionA cell-permeable, small-molecule c-Abl kinase activator with pEC50 of 6.1(EC50=794 nM); binds to the myristoyl binding site, also stimulates in vitro c-Abl phosphorylation; induces both pY245 (pEC50=5.6) and pY412 c-Abl phosphorylation; dose dependently induces Crk-L pY207 in KG-1 cells; the first small-molecule tool compound for c-Abl activation.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetBcr-Abl
-
RecptorBcr-Abl
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number484049-04-9
-
Formula Weight336.3198
-
Molecular FormulaC18H13FN4O2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESC1=CC=C(C=C1)N2C=C(C(=N2)C3=CC=C(C=C3)F)C4C(=O)NC(=O)N4
-
Chemical Name2,4-Imidazolidinedione, 5-[3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Yang J, et al. Chem Biol. 2011 Feb 25;18(2):177-86.
2. Cabigas EB, et al. J Cardiovasc Pharmacol Ther. 2015 Jan;20(1):93-103.
3. Grover P, et al. PLoS One. 2015 Jul 29;10(7):e0133590.
molnova catalog
related products
-
GNF-7
A potent and selective type-II kinase inhibitor of Bcr-Abl.
-
BCR-ABL-IN-7
BCR-ABL-IN-7 is a WT and T315I mutant ABL kinase inhibitor.BCR-ABL-IN-7 potently inhibits WT and T315I mutant ABL kinase activity.BCR-ABL-IN-7 can be used in chronic myelogenous leukemia (CML) research.
-
Ponatinib
Ponatinib (AP 24534) is a potent, orally active pan-inhibitor of BCR-ABL kinase with IC50 of 0.37 and 2.0 nM for ABL and mutant ABLT315I, respectively.
